MRI with Contrast Enhancement in a Patient with Chronic Kidney Disease: to Contrast Have Not Be Denied. Where Should We Put the Comma?
This paper provides information on the prevalence of chronic kidney disease (CKD) in the population. In General, according to various studies, signs of kidney disease and/or reduced glomerular filtration rate (GFR) are detected on average in every tenth resident in different countries. It is extreme...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Luchevaya Diagnostika, LLC
2019-03-01
|
| Series: | Вестник рентгенологии и радиологии |
| Subjects: | |
| Online Access: | https://www.russianradiology.ru/jour/article/view/416 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | This paper provides information on the prevalence of chronic kidney disease (CKD) in the population. In General, according to various studies, signs of kidney disease and/or reduced glomerular filtration rate (GFR) are detected on average in every tenth resident in different countries. It is extremely important to identify such patients before MRI with contrast enhancement, otherwise non-compliance with international manuals on contrast agents could lead to nephrogenic systemic fibrosis (NSF). The data of the study of Gadobutrol in Renally Impaired Patients (GRIP) indicate a favorable safety profile of Gadovist® in patients with moderate and severe renal impairment. Taking into account the available safety data and current manuals on contrast agents, only NSF low risk gadolinium-based contrast agents can be used in patients with severe renal impairment. |
|---|---|
| ISSN: | 0042-4676 2619-0478 |